The Effects of Maturation and Dyslexia Risk on Neural Speech‐Sound Encoding and Discrimination at Preschool Stage
European Journal of Neuroscience · 2026
DOI: 10.1111/ejn.70450 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neuroscience, 2026. Verfasst von Sergio Navarrete-Arroyo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cognitive Brain Research Unit, Department of Psychology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Speech Perception, Dyslexia, Evoked Potentials, Auditory, Discrimination, Psychological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Finland, Jane and Aatos Erkko Foundation, Kela.
Abstract (Originalsprache)
Event‐related potentials (ERPs), and particularly change‐elicited mismatch responses (MMRs), are valuable tools for assessing early speech processing and promising markers of dyslexia risk. Yet, their maturation during the preschool stage remains poorly characterized. We determined the typical elicitation of ERPs and MMRs to speech sounds at preschool age (4–5 years), their maturation from early childhood (28 months) to preschool age, and the impact of dyslexia risk on them. To this end, we recorded obligatory ERPs to a repeating pseudoword and MMRs to five deviances at 4–5 years and compared them with a previously reported follow‐up at 28 months, in subgroups with versus without dyslexia risk in a large sample ( n ~ 150). In the full sample, including both control and at‐risk children, the 4‐ to 5‐year obligatory ERPs showed a P1–N2 pattern, while the MMRs included a mismatch negativity (MMN) followed by a late discriminative negativity (LDN). From 28 months to 4–5 years, P1 amplitude increased and latency decreased, whereas the N2 amplitude increased. MMN and LDN amplitudes increased and LDN latency decreased with age, whereas a positive MMR reported at 28 months was no longer evident at 4–5 years. Crucially, at‐risk children exhibited reduced MMN amplitudes at 4–5 years across deviants, suggesting deficient speech discrimination. Changes from 28 months to 4–5 years were similar in both subgroups. These findings establish a solid description of typical/atypical neural speech‐sound processing during preschool years, serving as a reference for future studies including interventions or clinical groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cognitive Brain Research Unit, Department of Psychology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Finnish Centre of Excellence in Music, Mind, Body and Brain, Department of Psychology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Finnish Centre of Excellence in Music, Mind, Body and Brain, Faculty of Educational Sciences, University of Helsinki, Helsinki, Finland.
ORCID-Profile: Sergio Navarrete-Arroyo
Förderung
- Research Council of Finland
- Jane and Aatos Erkko Foundation
- Kela
- Finnish National Agency of Education
- Oskar Öflund Foundation
- Yrjö Jahnsson Foundation
- Finnish Cultural Foundation
- Ella and Georg Ehrnrooth Foundation
Zitieren
APA
Navarrete-Arroyo, S., Nie, P., Virtala, P., & Kujala, T. (2026). The Effects of Maturation and Dyslexia Risk on Neural Speech‐Sound Encoding and Discrimination at Preschool Stage. European Journal of Neuroscience. https://doi.org/10.1111/ejn.70450
Vancouver
Navarrete-Arroyo S, Nie P, Virtala P, Kujala T. The Effects of Maturation and Dyslexia Risk on Neural Speech‐Sound Encoding and Discrimination at Preschool Stage. European Journal of Neuroscience. 2026. doi:10.1111/ejn.70450
BibTeX
@article{NavarreteArroyo2026,
author = {Navarrete-Arroyo, Sergio and Nie, Peixin and Virtala, Paula and Kujala, Teija},
title = {The Effects of Maturation and Dyslexia Risk on Neural Speech‐Sound Encoding and Discrimination at Preschool Stage},
journal = {European Journal of Neuroscience},
year = {2026},
doi = {10.1111/ejn.70450}
}
EUVIMED